PTC Therapeutics

About PTC Therapeutics

PTC Therapeutics is a global biopharmaceutical company dedicated to the discovery and development of innovative medicines for patients with rare diseases and other serious conditions. Founded in 1998, the company has established itself as a leader in the field of genetic medicine, focusing on the modulation of RNA to treat genetic disorders.

With a commitment to scientific excellence, PTC Therapeutics employs cutting-edge technology and a robust pipeline of drug candidates aimed at addressing unmet medical needs. The company’s flagship product, Translarna (ataluren), is designed to treat nonsense mutation Duchenne muscular dystrophy (nmDMD), showcasing PTC’s dedication to improving the lives of patients.

PTC Therapeutics operates with a vision to transform the treatment landscape for rare diseases through innovation and collaboration. The company actively engages with patient communities, healthcare professionals, and regulatory bodies to ensure that its therapies are accessible and effective.

In addition to its focus on nmDMD, PTC is exploring treatments for other genetic disorders, including spinal muscular atrophy (SMA) and cystic fibrosis. The company’s research efforts are supported by a strong intellectual property portfolio and strategic partnerships with leading academic institutions and biotechnology firms.

Headquartered in the UK, PTC Therapeutics is committed to fostering a diverse and inclusive workplace that encourages creativity and collaboration among its employees. The company believes that a strong corporate culture is essential for driving innovation and achieving its mission.

As PTC Therapeutics continues to grow, it remains steadfast in its goal to make a meaningful impact on the lives of patients worldwide. Through its dedication to research and development, PTC is poised to lead the way in the advancement of genetic medicine.